Evelo Biosciences to Present at the Morgan Stanley 17th Annual Global Healthcare Conference
A live audio webcast of the fireside chat will be available on the Investors section of the Evelo website at http://ir.evelobio.com/news-events. A replay of the webcast will be available for approximately 30 days following the presentation.
About
Evelo currently has three product candidates, EDP1066 and EDP1815 for the treatment of inflammatory diseases and EDP1503 for the treatment of cancer. Evelo is also advancing additional oral biologics through preclinical development in other disease areas.
For more information, please visit www.evelobio.com.
Contact
Investors:
stefan@evelobio.com
or
Media:
jcotrone@evelobio.com
Source: Evelo Biosciences, Inc.